RebrAIn joins the Charter for the Responsible Development of Neurotechnologies
RebrAIn is proud to announce its commitment to the Charter for the Responsible Development of Neurotechnologies, a collective initiative led by public and private stakeholders and supported by the French National Consultative Ethics (CCNE). This initiative is part of...
Challenges showcases RebrAIn’s AI-powered innovation in Parkinson’s surgery
Challenges underscores the significance of RebrAIn’s technology in enhancing the precision and efficiency of deep brain stimulation (DBS) surgeries. By leveraging machine learning algorithms trained on extensive clinical data, RebrAIn’s software assists...
From Patient to Practice: RebrAIn Wins the Resah Tender
The Strategic Importance of This Tender This success marks a major strategic turning point for RebrAIn, as the Resah procurement center plays a key role in the public healthcare sector in France. By enabling the member hospitals to choose the most effective...
The FUS Foundation highlights RebrAIn’s advances and validates its Board
Recently, the Focused Ultrasound Foundation highlighted RebrAIn’s success in obtaining its second FDA 510(k) approval – which extends the capabilities of its OptimMRI software to include new machine learning models for lesioning treatment of Essential...
RebrAIn Hosts Inaugural Medical Advisory Board Meeting (MAB)
RebrAIn recently held the inaugural meeting of its Medical Advisory Board (MAB), marking a significant milestone in the company’s ongoing mission to deliver transformative AI-powered tools to neurosurgeons. The meeting also underscored RebrAIn’s pivotal role in...
RebrAIn completes enrollment ahead of schedule for PARKEO2 clinical trial
RebrAIn is pleased to announce the early completion of enrollment for the second phase of the PARKEO2 clinical trial, a pioneering study aimed at improving surgical treatments for Parkinson’s disease. Sponsored by the Bordeaux University Hospital (CHU de Bordeaux) and...
RebrAIn Co-Founders to Present Innovative VIM Targeting Techniques at WSSFN Biennial Meeting
RebrAIn is excited to announce that its co-founders, Prof. Emmanuel Cuny, MD, and Prof. Nejib Zemzemi, PhD, will be presenting groundbreaking research on VIM targeting techniques at the upcoming World Society for Stereotactic and Functional Neurosurgery (WSSFN)...
RebrAIn Achieves Second FDA 510(k) Clearance, Advancing AI-Powered Neurosurgical Targeting
RebrAIn is proud to announce its second FDA 510(k) clearance for the OptimMRI software, marking another significant milestone in our mission to revolutionize neurosurgical targeting through cutting-edge AI technology. This clearance expands our capabilities to assist...